Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.
Microbial Chemistry Research Foundation, Institute of Microbial Chemistry (BIKAKEN), Numazu-shi, Japan.
Monoclon Antib Immunodiagn Immunother. 2022 Feb;41(1):32-38. doi: 10.1089/mab.2021.0056.
Trophoblast cell surface antigen 2 (TROP2) has been reported to be overexpressed in many cancers, and is involved in cancer cell proliferation, invasion, and metastasis. We previously developed a highly sensitive anti-TROP2 monoclonal antibody (mAb) (clone TrMab-6; mouse IgG, kappa) using a Cell-Based Immunization and Screening method. TrMab-6 is useful for investigations using flow cytometry, Western blotting, and immunohistochemistry and possesses antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against TROP2-expressing triple-negative breast cancer (TNBC) cell lines, such as MDA-MB-231 and MDA-MB-468. This study investigated whether TrMab-6 possesses antitumor activities via ADCC/CDC activities using mouse xenograft models of TNBC cell lines. experiments on MDA-MB-231 and MDA-MB-468 xenografts revealed that TrMab-6 significantly reduced tumor growth compared with normal mouse IgG treatment. The findings of this study suggest that TrMab-6 is a promising treatment option for TROP2-expressing TNBC.
滋养层细胞表面抗原 2（TROP2）在许多癌症中过表达，并且参与癌细胞增殖、侵袭和转移。我们之前使用基于细胞的免疫接种和筛选方法开发了一种高灵敏度的抗 TROP2 单克隆抗体（mAb）（克隆 TrMab-6；鼠 IgG，kappa）。TrMab-6 可用于流式细胞术、Western blot 和免疫组织化学研究，对表达 TROP2 的三阴性乳腺癌（TNBC）细胞系（如 MDA-MB-231 和 MDA-MB-468）具有抗体依赖性细胞毒性（ADCC）和补体依赖性细胞毒性（CDC）。本研究通过 TNBC 细胞系的小鼠异种移植模型研究了 TrMab-6 是否通过 ADCC/CDC 活性具有抗肿瘤活性。在 MDA-MB-231 和 MDA-MB-468 异种移植实验中，TrMab-6 与正常鼠 IgG 治疗相比，显著降低了肿瘤生长。这项研究的结果表明，TrMab-6 是一种有前途的 TROP2 表达型 TNBC 治疗选择。
